Figure 1.
Flow diagram of subject follow-up with transition to different stages. Note: all subjects who were withdrawn due to termination of the study by the sponsor were eligible to continue receiving mepolizumab on a compassionate use protocol.
Flow diagram of subject follow-up with transition to different stages. Note: all subjects who were withdrawn due to termination of the study by the sponsor were eligible to continue receiving mepolizumab on a compassionate use protocol.